Personalis Announces NeXT Level Biomarkers Symposium
22.6.2021 16:01:00 EEST | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform™.
This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS™). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis.
The agenda for NeXT Level Biomarkers Symposium will cover:
- Biomarker Discovery with ImmunoID NeXT Platform®
- Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm
- Neoantigen Binding Prediction and Biomarker Discovery with SHERPA™
- Composite Biomarkers and our Neoantigen Presentation Score (NEOPS™)
- Parker Institute Case Study: The PRINCE Trial
- NeXT Liquid Biopsy™ Overview and Review of AACR Data
- NeXT Dx™ and Companion Diagnostics (CDx) with Personalis
“We are excited to share our latest technology and product advances with our partners,” said Richard Chen, MD, Personalis CSO. “Given the complex biology underlying cancer progression and response to treatment, our mission at Personalis is to provide broader, more comprehensive molecular profiling and testing for each patient’s cancer, thereby giving biopharma, physicians, and patients the information they need for precision oncology now and with an eye to the future. These new technologies help further that mission.”
Further information, including registration information, on the NeXT Level Biomarkers Symposium can be found at this link.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency, and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005462/en/
Contact information
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 10:00:00 EEST | Press release
Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global operations, delivering measurable improvements in lead time, cost, quality, and productivity. “Manufacturers don’t need more AI pilots. They need AI that runs at scale in production,” said Jonathan Wu, Chief
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 10:00:00 EEST | Press release
Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global operations, delivering measurable improvements in lead time, cost, quality, and productivity. “Manufacturers don’t need more AI pilots. They need AI that runs at scale in production,” said Jonathan Wu, Chief
Bringg Welcomes Chris Conway as Senior Vice President and General Manager, EMEA21.4.2026 08:00:00 EEST | Press release
Bringg, the last-mile performance leader, today announced Chris Conway's appointment as Senior Vice President and General Manager, EMEA. Conway will lead Bringg's commercial strategy, customer relationships, and go-to-market operations across the region. Conway brings more than 20 years of experience in eCommerce, digital commerce, and operational transformation at three of the UK's largest grocery retailers. Most recently, he served as Managing Director of Quick Commerce and Food Operating Board Member at Co-op, where he built and scaled a £500 million-plus q-commerce operation delivering from nearly 2,000 stores. He also founded Peckish, a rapid delivery app that gave independent retailers access to q-commerce technology. He also led Asda's online grocery business to more than £1 billion in revenue and 20% market share, and ran the online commercial team at Morrisons. Conway holds an AI certificate from Oxford Saïd Business School. “Chris built one of the UK's most successful deliver
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 08:00:00 EEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 08:00:00 EEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom